TY - JOUR
T1 - The prevalence of pseudoxanthoma elasticum
T2 - Revised estimations based on genotyping in a high vascular risk cohort
AU - Kranenburg, Guido
AU - Baas, Annette F.
AU - de Jong, Pim A.
AU - Asselbergs, Folkert W.
AU - Visseren, Frank L.J.
AU - Spiering, Wilko
N1 - Funding Information:
We gratefully acknowledge D. Dooijes (clinical laboratory geneticist) for his help with available genetic databases. Also, we gratefully acknowledge the SMART research nurses; R. van Petersen (data-manager); B.G.F. Dinther (vascular manager) and the participants of the SMART Study Group: A. Algra MD,PhD; Y. van der Graaf, MD,PhD; D.E. Grobbee, MD,PhD; G.E.H.M. Rutten, MD,PhD, Julius Center for Health Sciences and Primary care; F.L.J.Visseren, MD,PhD, Department of Internal Medicine; G.J. de Borst, MD,PhD, Department of Vascular Surgery; L.J. Kappelle, MD,PhD, Department of Neurology; T. Leiner, MD,PhD, Department of Radiology; P.A. Doevendans, MD,PhD, Department of Cardiology.
Publisher Copyright:
© 2018
PY - 2019/2
Y1 - 2019/2
N2 - Background: Pseudoxanthoma elasticum (PXE), an autosomal recessive systemic calcification disorder, is caused by mutations in the ABCC6-gene and associated with severe visual impairment and peripheral arterial disease. Given the progress in development of a therapy for PXE, more precise estimations of its prevalence are warranted. Methods: We genotyped the four most common ABCC6 mutations (c.3421C > T, c.4182delG, c.3775delT, c.2787+1G > T), together accounting for half of all ABCC6 mutations identified in PXE patients from the Dutch population, in a Dutch high vascular risk cohort (n = 7893). The obtained allele frequencies were used to estimate the prevalence of PXE using the Hardy-Weinberg equilibrium. Results: The carrier frequency of ABCC6 was 0.60% for c.3421C > T, 0.17% for c.4182delG, 0.05% for c.3775delT and 0.03% for c.2787+1G > T. The prevalence of PXE based upon the allele frequencies of these four mutations was estimated as 1 per 56,000 (95%CI 1 per 35,000–97,000). Conclusion: The prevalence of PXE is at least 1 per 56,000 meaning that there would be at least 307 affected individuals in the Netherlands that may benefit from a potential upcoming treatment. Since this estimate is based on mutations together accounting for half of all ABCC6 mutations identified among PXE patients, the actual prevalence will probably be higher.
AB - Background: Pseudoxanthoma elasticum (PXE), an autosomal recessive systemic calcification disorder, is caused by mutations in the ABCC6-gene and associated with severe visual impairment and peripheral arterial disease. Given the progress in development of a therapy for PXE, more precise estimations of its prevalence are warranted. Methods: We genotyped the four most common ABCC6 mutations (c.3421C > T, c.4182delG, c.3775delT, c.2787+1G > T), together accounting for half of all ABCC6 mutations identified in PXE patients from the Dutch population, in a Dutch high vascular risk cohort (n = 7893). The obtained allele frequencies were used to estimate the prevalence of PXE using the Hardy-Weinberg equilibrium. Results: The carrier frequency of ABCC6 was 0.60% for c.3421C > T, 0.17% for c.4182delG, 0.05% for c.3775delT and 0.03% for c.2787+1G > T. The prevalence of PXE based upon the allele frequencies of these four mutations was estimated as 1 per 56,000 (95%CI 1 per 35,000–97,000). Conclusion: The prevalence of PXE is at least 1 per 56,000 meaning that there would be at least 307 affected individuals in the Netherlands that may benefit from a potential upcoming treatment. Since this estimate is based on mutations together accounting for half of all ABCC6 mutations identified among PXE patients, the actual prevalence will probably be higher.
KW - ABCC6
KW - Prevalence
KW - Pseudoxanthoma elasticum
KW - Multidrug Resistance-Associated Proteins/genetics
KW - Netherlands
KW - Gene Frequency
KW - Humans
KW - Heterozygote
KW - Pseudoxanthoma Elasticum/epidemiology
KW - Genetic Carrier Screening
KW - Polymorphism, Genetic
UR - http://www.scopus.com/inward/record.url?scp=85047451737&partnerID=8YFLogxK
U2 - 10.1016/j.ejmg.2018.05.020
DO - 10.1016/j.ejmg.2018.05.020
M3 - Article
C2 - 29800625
AN - SCOPUS:85047451737
SN - 1769-7212
VL - 62
SP - 90
EP - 92
JO - European Journal of Medical Genetics
JF - European Journal of Medical Genetics
IS - 2
ER -